Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes following reports of some remarkable responses in individual patients. The situation is complicated by the fact that these agents do not appear to work via their attachment to endogenous cannabinoid receptors. Their pharmacokinetics are complex, and bioavailability is variable, resulting in difficulty in developing a suitable formulation for oral delivery.
| INTRODUCTION
Cannabis has been used by humanity in a variety of medical settings via a range of different formulations for more than 5000 years. Gowers in his book "Epilepsy and other Convulsive Diseases" recommended its prescription as follows: "It is of small value as an adjunct to bromide, but is sometimes of considerable service given separately." 1 Of interest, he cited a case of a man aged 40, who had had tonic-clonic seizures for 25 years. He failed to respond to treatment with potassium bromide, but became seizure-free on "Indian hemp," which "wrought a wonderful change." This scenario appears to have been repeated more recently. A miraculous response has been reported anecdotally in children, who experienced a "neurological awakening" after taking a cannabidiol preparation, which substantially stimulated public awareness. 2 This phenomenon has encouraged a high level of interest among physicians, medicinal chemists, pharmaceutical companies, and the general population, and occasioned impassioned pleas from families with children with severe epilepsy for access to cannabis derivatives. 3 In this short commentary, we summarize the pharmacology and therapeutic use of cannabinoid derivatives in the treatment of epilepsy and highlight the problems lying ahead in testing and regulating a formulation suitable for everyday clinical use.
| PHARMACOLOGY
The mechanism of action, pharmacokinetics, and pharmacodynamics of the cannabinoids are complex. The cannabis plant contains 1000 phytocannabinoids and terpenes that work through a number of complex signaling networks in the body. 4 Endocannabinoids have important regulatory roles throughout the nervous and immune systems. They cross the blood-brain barrier and distribute to all lipid-laden tissue, including brain parenchyma and neuronal cell membranes. The endocannabinoid system comprises CB 1 receptors, expressed mainly by central and peripheral neurons, and CB 2 receptors, expressed mainly by immune cells. 5 A range of enzyme and uptake systems appear to be involved in their metabolism, including cyclooxygenase 2 (COX-2) and fatty acid amide hydrolase 1. 6 Endocannabinoids are rapidly removed from the body by hydrolysis.
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CB 1 receptors reduce neuronal excitability and neurotransmitter release by opening K + channels and blocking Ca 2+ channels. 8 These pharmacologic effects have a broad relevance for the analgesic, antispasticity, cardiovascular, and respiratory effects of this ubiquitous physiologic and pharmacologic system. CB 2 receptors are implicated in immune regulation. They appear also to be expressed in neurons. 9 Thus cannabinoids provide a broad potential therapeutic target for a wide range of disorders, including nausea, pain, neuromodulation, inflammation, cancer, cardiovascular disease, spasticity, and, of course, epilepsy. 8 The 2 cannabinoids that have attracted the most attention for treating epilepsy are delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD). More recently, trials have been begun with cannabidivarin (CBDV), which is the propyl analog of CBD. Although THC is responsible for most of the psychiatric effect of marijuana, CBD and CBDV appear to lack these complicating properties. 4 For this reason no effort has been made to develop THC as an anticonvulsant drug.
| CANNABINOIDS FOR EPILEPSY
The molecule most studied for the treatment of epilepsy is CBD. 10 Its mechanisms of action are complex, and as yet, not entirely clear. 11 Cannabis derivatives have multiple pharmacologic targets. 4 CBD has a low affinity for the endocannabinoid receptors and so a range of other pharmacologic effects have been mooted to explain its antiseizure properties, including those on traditional voltage-gated sodium and calcium ion channels. 12 These compounds may provide specific efficacy for some children with Dravet syndrome expressed by aberrant epilepsy-associated Nav1.6 mutant sodium channels. 13 There are a range of other possible targets for CBD, which may be relevant to its antiseizure and other pharmacologic effects. 14 Although chemically similar to CBD, there are few data exploring the mechanism of action of CBDV. Both, however, have similar effects on rodent seizure models. 15 The metabolism of CBD and CBDV is complex and generally unfavorable for oral use. Both have a very low oral bioavailability, estimated to be less than 10%.
14 Part of this is due to their very high first-pass metabolism in the gut wall and liver, resulting in poor and inconsistent absorption from the gastrointestinal tract. 16 CBD and CBDV are oxidized by a range of cytochrome P450 (CYP) isoenzymes, particularly CYP3A4, CYP2C9, and CYP2C19. 17 There are likely to be active metabolites with both molecules. 16 The elimination half-lives of CBD and CBDV are within the range of 18-32 hours, permitting once or twice daily dosing. 18 These complicating and unhelpful pharmacologic properties result in inconsistent absorption, bioavailability, and metabolism, confining CBD and CBDV to being delivered currently in oil-based capsules or suspensions, resulting in a range of bioavailabilities in babies, children, adolescents, and adults with epilepsy.
Cannabidiol may be implicated in inhibition and induction of some CYP isoenzymes, which could result in a range of pharmacokinetic interactions with other therapeutic agents, including antiepileptic drugs (AEDs). Thus this molecule is a powerful inhibitor of CYP3A4, CYP2C9, and CYP2C19. 16 The situation with CBDV is still unclear, although a similar adverse pharmacokinetic scenario is likely. These pharmacokinetic interactions have the potential to substantially complicate the management of refractory epilepsy in patients already established on a range of AEDs. Thus CBD is known to inhibit the metabolism of clobazam and its active metabolite N-desmethylclobazam, thereby increasing its sedative properties. 19 Other targets for CBD inhibition include topiramate, zonisamide, and eslicarbazepine acetate. 20 All in all, these adverse pharmacokinetic properties have the potential to substantially complicate the therapeutic use of CBD and encourages further studies with CBDV in the hope that a more predictable oral formulation of this moiety can be developed for subsequent licensing. Like CBD, the antiseizure effects of CBDV are not mediated by CB 1 receptors, and both of these molecules may possibly have other unique mechanisms of action. 21 Key Points
• There is substantial interest in the use of cannabinoids for the treatment of epileptic seizures
• Their pharmacokinetics are complex, making it difficult to identify a suitable formulation for oral use
• Recent randomized placebo-controlled trials support the efficacy of cannabinoids for Dravet and Lennox-Gastaut syndromes
• There are still many problems to overcome before this group of drugs can be used routinely for treatment of the common epilepsies
| EFFICACY DATA
The controversy concerning the use of CBD for epilepsy is a hot topic. Many lectures have been given and papers written about the pros and cons of giving marijuana derivatives to children and adults with refractory epilepsy. It is understandable that parents and older patients will try all available options to stop the seizures, and so this initiative began with individual reports of the success of cannabis derivates from parents desperate to see these compounds as a panacea for just about every type of epilepsy. Charlotte's Web was the first publicized indication that medical marijuana would help, and the TV News conglomerate, CNN, was fast to broadcast the experience of just one child. 2 Charlotte is a little girl with refractory SCNIA-confirmed Dravet syndrome, whose epilepsy responded to a strain of cannabis, now known as Charlotte's web. That single newscast still remains on the minds of many with epilepsy, and now there is a frenetic effort to try it in any form by many families with a severely affected child.
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The epilepsy professional community, of course, has seen the use of cannabinoids for epilepsy in another way. Physicians have to be "evidence based," which entails undertaking randomized, double-blind, placebo-controlled clinical trials (RCTs). With the wish to be "cured" by marijuana so extensive in the community, it is imperative that studies are blinded and well designed. Otherwise, results can be misleading and overly optimistic. Recent open-label "real world" studies have reported mixed results, generally more positive than in double-blind trials. [25] [26] [27] [28] The largest such study recruited 214 patients, but only 137 patients (or 64%) could be included in the efficacy analysis. 28 The patients in this trial had a variety of epilepsy syndromes, but the overall results were positive, with a reduction in motor seizures of 35.5% in the group where efficacy could be assessed. The main adverse events were somnolence (25%), decreased appetite (19%), diarrhea (19%), and fatigue (13%).
| CLASS 1 CLINICAL TRIALS
Fortunately, the regulators have looked upon CBD (and other marijuana-based substances) as drugs that should be appropriately tested like all other compounds used to treat epilepsy. At the present time some of the RCTs for specific types of epilepsy syndromes are just being completed, and soon there will be more placebo-controlled data to report, which will help answer the question as to whether CBD is a safe and effective treatment for epilepsy. All the randomized regulatory trials were analyzed on an intention-to-treat basis, with the doses of coadministered AEDs being kept constant.
The first completed randomized trials have been for specific epilepsy syndromes, where patients have had few suitable therapeutic alternatives. The only RCT data currently published in a peer-reviewed journal are on the efficacy of CBD for Dravet syndrome. 29 For other indications, such as tuberous sclerosis and Lennox-Gastaut syndrome, phase 3 trials have been completed and manuscripts are being prepared. The only available public information from these studies is derived from peer-reviewed posters presented at the American Epilepsy Society meeting in 2016, with the same posters being viewed at the American Academy of Neurology and the German, Austrian, and Swiss Epilepsy Societies annual meetings during the next year. 30, 31 Several pharmaceutical companies are in the process of testing different formulations of CBD. A comprehensive overview of all the clinical trials being conducted and all the pharmaceutical companies involved in the programme can be obtained on the website ClinicalTrials.gov. The first completed and published RCT concerns the efficacy of CBD in patients with Dravet syndrome. 29 A total of 120 young adults with drug-resistant convulsive seizures were included in the study. Sixty-one patients were randomized into the active CBD group and 59 into the placebo control comparison. This sample size gave 80% power to detect an absolute difference of 32% between the primary end points. Patients received either placebo or CBD oral solution in a dose of 20 mg/kg, together with all concomitant AEDs that were being taken at the first visit.
There was a 4-week baseline and a 14-week treatment period, with uptitration of 2 weeks and maintenance of 12 weeks or 3 months. The primary end point was the change in convulsive seizure frequency over the entire 14-week treatment period as compared with the 4-week baseline. Secondary end points were 50% seizure reduction per month, as well as improvement in the Caregiver Global Impression of Change (CGIG) scale. The mean age of the patients was 9.8 years (range 2.3-18.4 years). The baseline seizure frequency was 13 seizures per month, consisting mostly of generalized tonic-clonic seizures. Ninety percent of patients (n = 108) completed the study, most of whom (n = 105) entered the open-label study extension. The most common concomitant antiepileptic medications were clobazam, sodium valproate, stiripentol, levetiracetam, and topiramate. Many of the children had developmental delay (114 of 118 with reliable data), which was judged to be profound in 48%. Efficacy appeared to favor CBD, with 50% responder rate (≥50% seizure reduction compared to baseline) in 43% of the active medication group and 27% with placebo. Five percent of the patients became seizure-free in the active group versus none taking placebo. There was no difference between active drug and placebo for seizure types other than convulsive episodes. For the primary end point there was a decrease from a median of 12.4 seizures a month at baseline in the active group to 5.9 seizures per month at the end of the maintenance period. For the placebo group, the median monthly change was from 14.9 to 14.1 seizures per month. The median decrease in the treatment group was 38.9% versus 13.3% in the placebo group. Significance was at the P = .01 for the primary outcome and for the secondary outcomes P = .08 for responder rate and P = .02 for change in CGIG scale.
The main adverse events in this study were diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal liver function test results. Withdrawals due to adverse events occurred in 8 patients from the CBD group and in one taking placebo. There was a potential interaction with sodium valproate, which was reflected by an increase in aminotransferase levels. 20 Somnolence was seen mainly in patients taking concomitant clobazam, as a consequence of higher circulating plasma levels of the parent drug and active metabolite. 19 The authors concluded that CBD had a positive effect in patients with Dravet syndrome. Adverse events were more likely to occur in the active than the placebo group. These were usually mild or moderate in intensity. Lennox-Gastaut syndrome is also very difficult to treat, with most patients never becoming seizure-free. Two CBD RCTs for patients with this complex disorder have been completed and presented as posters as mentioned earlier. 30, 31 For the first study, placebo was compared to an oral solution of 20 mg/kg CBD. Patients with a wide range of ages (2-55 years) were included. 30 They had to report at least 2 drop attacks per week during the 4-week baseline. The primary end point was a change in monthly drop seizure frequency during the 14-week treatment phase (2 weeks of titration and 12 weeks of maintenance). Drop seizures included atonic, tonic, or tonic-clonic seizures that led to a fall. A total of 171 patients were randomized. The target dose of CBD was 20 mg/kg given twice daily. There were 86 patients in the CBD group (30 patients were >18 years old) and 85 in the placebo group (28 patients >18 years old). Fourteen patients randomized to CBD and one taking placebo withdrew from the study. During the treatment period there was a median 44% reduction in drop seizures for the CBD group and 22% for placebo (P = .0135). The median percent change for non-drop seizures was 49% for the active group and 23% for placebo (P = .01). Three patients from the CBD group but none taking placebo were drop-seizure-free during the maintenance period. As in the Dravet syndrome trial, the most frequent adverse events reported by >10% of the patients were diarrhea, somnolence, pyrexia, decreased appetite, and vomiting. Most resolved either spontaneously or through dose reduction and were deemed to be mild or moderate.
The second Lennox-Gastaut study was similar to the first, but compared 2 doses of CBD to placebo. 32 Patients were randomized to either 10 mg/kg or 20 mg/kg of CBD versus placebo. There were 225 patients randomized. Age range was again from 2-55 years. There were 76 patients in the CBD 20 mg/kg group, 73 in the CBD 10 mg/kg group, and 76 in the placebo group. Both doses (10 and 20 mg/kg) of CBD produced significantly greater reductions in drop seizures, with higher responder rates and a greater proportion of caregivers/patients reporting an improvement in their overall condition, compared to placebo. As in the other 2 studies, there were more adverse events reported in the treatment groups than in those with placebo. Patients taking CBD 20 mg/kg reported more adverse events than did patients in the 10 mg/kg group. Cannabidiol is being tried for other syndromes such as infantile spasms and Sturge-Weber syndrome, but so far only scanty unreliable open-label pilot study data are available. For example, only 5 patients were included in a Sturge-Weber study. 32 The patients were followed for about 14 weeks. One withdrew because of lack of efficacy and 4 seemed to improve and stayed on the drug for over 60 weeks. Obviously, these results do not provide enough evidence to draw conclusions as to the drug's efficacy or effectiveness in this patient group. However, for Dravet and Lennox-Gastaut syndromes, class 1 evidence of efficacy is now available. The conclusion is that CBD, at least in the syndromes tested so far, can be an effective alternative to currently available options. It does not seem to be a wonder drug, but may be useful for some patients with these difficult to treat condition, where little else has made an impact. The patients who participated in the above-mentioned 3 studies had failed to respond to treatment with at least 6 AEDs and were taking 2-3 other drugs at the time of the trial. Despite this, some patients attained seizure freedom. This phenomenon needs further investigation!
| CONCLUSIONS
What do we know? We know that cannabinoids have antiseizure properties. We know that they have complex and largely unhelpful pharmacokinetics. We know that they probably do not work for epilepsy via the endocannabinoid system. We know that they interact pharmacokinetically with a range of other therapeutic substances, including AEDs. We know that their side-effect profile is not likely to be unique among antiseizure drugs. We know that they work remarkably well in a few children with very bad epilepsy. What don't we know? We don't know how they work. We don't know how to produce a formulation with consistent pharmacokinetics suitable for a major clinical trial program. We don't yet know whether they will make a major difference in the lives of most people with pharmacoresistant epilepsy and those who care for them. We don't know why a few patients appear to have a miraculous response to cannabis derivatives. We think that there may be a genetic reason for this. Hopefully, the high level of public and scientific interest in cannabinoids will stimulate the production of an easy-to-formulate molecule that has the potential to answer at least some of the preceding questions without too much delay.
